Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002744 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
A Phase 3 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,970
- Enrollment target
NCT00002744: Completed Phase 3 study, sponsored by Children's Oncology Group.
NCT00002744 is a Phase 3 study that has completed, run by Children's Oncology Group. The registered enrollment target is 1,970 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (155% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002744, a Phase 3 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,970 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more cancer cells. It is not yet known which regimen of combination chemotherapy is more effective for acute lymphoblastic leukemia PURPOSE: Randomized phase III trial to compare different regimens of combination chemotherapy in treating children who have newly diagnosed acute lymphoblastic leukemia.
Primary Outcome
Primary outcome index used in examining the randomized treatment groups will be event-free survival (EFS) from the time of randomization (i.e., end of Induction), where the life table events will consist of the first occurrence of leukemic relapse at any site, death, or occurrence of a second malignancy.
Interventions
- DRUG cyclophosphamide
- DRUG dexamethasone
- DRUG cytarabine
- DRUG asparaginase
- DRUG daunorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,970 participants |
| Start Date | 1996-05 |
| Est. Completion | 2007-03 |
| Phase | Phase 3 |
What the finished NCT00002744 record still lists
NCT00002744 is an interventional study that assigns participants to a tested intervention. Its 1,970 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (155% higher).
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00002744 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002744 about?
NCT00002744 is a clinical study titled "Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more cancer cells. It is not yet known which regimen of combination chemotherapy is more effective for acut...
What is the current status of trial NCT00002744?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,970 participants. The study started on 1996-05. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00002744?
The interventions under investigation include: cyclophosphamide (DRUG), dexamethasone (DRUG), cytarabine (DRUG), asparaginase (DRUG), daunorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00002744?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002744's enrollment target sits among peer trials
1,970 107th of 2000 higher than 1,894 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06062394 · 1,980 participants · NA
Penn Medicine Healthy Heart
- NCT07321886 · 1,980 participants · Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- NCT04251052 · 1,956 participants · NA
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia